RxDoctor Payments Data

Sarah Shim

Optometrist · Dalton, GANPI 1598070955

Payments from drug & device makers

$3,561in general payments, 2019–2025

Across 131 payments — averaging $27.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$792
  • Johnson & Johnson Vision Care, Inc.$623
  • Alcon$587
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$457
  • Coopervision Inc.$282
  • Sun Pharmaceutical Industries Inc.$186
  • plus $634 from 10 others

What the payments were for

  • Food & beverage$3,550100%
  • Education$110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,561 in reported general payments places this provider in the 80th percentile of 1,285 optometrist providers in Georgia.

See all optometrist providers in Georgia

Medicare billing

Part B allowed, 2024
$200,305
Medicare patients
683
Services billed
5,856

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine57$52,767
MieboPerfluorohexyloctane/Pf35$27,707
LumiganBimatoprost55$22,225
Cyclosporine37$17,503
XiidraLifitegrast19$12,853
Alphagan PBrimonidine Tartrate18$7,824
RocklatanNetarsudil Mesylat/Latanoprost12$6,894
Lotemax SmLoteprednol Etabonate21$5,510
CombiganBrimonidine Tartrate/Timolol21$4,461
Brimonidine Tartrate45$2,825
Latanoprost239$2,436
Fluorometholone15$1,010
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat58$775
Tobramycin-DexamethasoneTobramycin/Dexamethasone19$635
Timolol Maleate71$631

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P, Combigan$170$87,278151 claims
Bausch & Lomb Americas Inc.Miebo, Xiidra$792$40,56054 claims
Aerie Pharmaceuticals, Inc.Rocklatan$98$6,89412 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm$457$5,51021 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,285 optometrist providers in Georgia.

Other optometrist in Dalton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →